Hromas, Robert

Transcription Factors, Normal Myeloid Development, and Leukemia

Tenen, D. G., Hromas, R., Licht, J. D., & Zhang, D.-E. (1997) · Blood

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 735

A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity

Khan, S., Zhang, X., Lv, D., Zhang, Q., He, Y., Zhang, P., Liu, X., Thummuri, D., Yuan, Y., Wiegand, J. S., et al. (2019) · Nature Medicine

Protein Degradation and InhibitorsCell death mechanisms and regulation

Cited by 688

The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1.

May, W. A., Lessnick, S. L., Braun, B. S., Klemsz, M., Lewis, B. C., Lunsford, L. B., Hromas, R., & Denny, C. T. (1993) · Molecular and Cellular Biology

Sarcoma Diagnosis and TreatmentChromatin Remodeling and Cancer

Cited by 497

Cutting edge: IL-17D, a novel member of the IL-17 family, stimulates cytokine production and inhibits hemopoiesis

Starnes, T., Broxmeyer, H. E., Robertson, M. J., & Hromas, R. (2002) · The Journal of Immunology

Cytokine Signaling Pathways and InteractionsPsoriasis: Treatment and Pathogenesis

Cited by 331

Hematopoietic lineage- and stage-restricted expression of the ETS oncogene family member PU.1

Hromas, R., Orazi, A., Neiman, R., Maki, R., Van Beveran, C., Moore, J., & Klemsz, M. (1993) · Blood

Hematopoietic Stem Cell TransplantationAcute Myeloid Leukemia Research

Cited by 216

Elimination of Radiation-Induced Senescence in the Brain Tumor Microenvironment Attenuates Glioblastoma Recurrence

Fletcher-Sananikone, E., Kanji, S., Tomimatsu, N., Di Cristofaro, L. F. M., Kollipara, R. K., Saha, D., Floyd, J. R., Sung, P., Hromas, R., Burns, T. C., et al. (2021) · Cancer Research

Telomeres, Telomerase, and SenescenceGlioma Diagnosis and Treatment

Cited by 212

Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity,

Lv, D., Pal, P., Liu, X., Jia, Y., Thummuri, D., Zhang, P., Hu, W., Pei, J., Zhang, Q., Zhou, S., et al. (2021) · Nature Communications

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 158

Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies

He, Y., Khan, S., Huo, Z., Lv, D., Zhang, X., Liu, X., Yuan, Y., Hromas, R., Xu, M., Zheng, G., et al. (2020) · Journal of Hematology & Oncology

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 126

MiR223-3p promotes synthetic lethality in BRCA1-deficient cancers

Srinivasan, G., Williamson, E. A., Kong, K., Jaiswal, A. S., Huang, G., Kim, H.-S., Schärer, O., Zhao, W., Burma, S., Sung, P., et al. (2019) · Proceedings of the National Academy of Sciences

DNA Repair MechanismsMicroRNA in disease regulation

Cited by 28

The Wave2 scaffold Hem-1 is required for transition of fetal liver hematopoiesis to bone marrow

Shao, L., Chang, J., Feng, W., Wang, X., Williamson, E. A., Li, Y., Schajnovitz, A., Scadden, D., Mortensen, L. J., Lin, C. P., et al. (2018) · Nature Communications

Hematopoietic Stem Cell TransplantationBlood disorders and treatments

Cited by 20